Compare SEVN & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEVN | IPHA |
|---|---|---|
| Founded | 1986 | 1999 |
| Country | United States | France |
| Employees | N/A | 163 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.4M | 165.3M |
| IPO Year | 2008 | N/A |
| Metric | SEVN | IPHA |
|---|---|---|
| Price | $7.65 | $1.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $10.50 | $5.75 |
| AVG Volume (30 Days) | ★ 159.5K | 5.3K |
| Earning Date | 04-28-2026 | 03-26-2026 |
| Dividend Yield | ★ 13.90% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $29,383,000.00 | N/A |
| Revenue This Year | $27.75 | $180.36 |
| Revenue Next Year | $4.06 | N/A |
| P/E Ratio | $40.11 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.37 | $1.18 |
| 52 Week High | $11.15 | $2.62 |
| Indicator | SEVN | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 45.08 |
| Support Level | N/A | $1.60 |
| Resistance Level | N/A | $1.78 |
| Average True Range (ATR) | 0.00 | 0.06 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 0.00 | 17.29 |
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in originating and investing in floating-rate first mortgage loans secured by middle-market and transitional commercial real estate. Its primary objective is to balance capital preservation with the generation of risk-adjusted returns. The company operates in one business segment: originating and investing in floating-rate first mortgage loans secured by CRE properties.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.